The anticancer actions of the biguanide metformin involve the functioning of the ser-ine/glycine one-carbon metabolic network. We report that metformin directly and specifically targets the enzymatic activity of mitochondrial serine hydroxymethyltransferase (SHMT2). In vitro competitive binding assays with human recombinant SHMT1 and SHMT2 isoforms revealed that metformin preferentially inhibits SHMT2 activity by a non-catalytic mechanism. Computational docking coupled with molecular dynamics simulation predicted that metformin could occupy the cofactor pyridoxal-5′-phosphate (PLP) cavity and destabilize the formation of catalytically active SHMT2 oligomers. Differential scanning fluorimetry-based biophysical screening confirmed that metformin diminishes the capacity of PLP to promote the conversion of SHMT2 from an inactive, open state to a highly ordered, catalytically competent closed state. CRISPR/Cas9-based disruption of SHMT2, but not of SHMT1, prevented metformin from inhibiting total SHMT activity in cancer cell lines. Isotope tracing studies in SHMT1 knock-out cells confirmed that metformin decreased the SHMT2-channeled serine-to-formate flux and restricted the formate utilization in thymidylate synthesis upon overexpression of the metformin-unresponsive yeast equivalent of mitochondrial complex I (mCI). While maintaining its capacity to inhibit mitochondrial oxidative phosphorylation, metformin lost its cytotoxic and antiproliferative activity in SHMT2-null cancer cells unable to pro-duce energy-rich NADH or FADH2 molecules from tricarboxylic acid cycle (TCA) metabolites. As currently available SHMT2 inhibitors have not yet reached the clinic, our current data establishing the structural and mechanistic bases of metformin as a small-molecule, PLP-competitive inhibitor of the SHMT2 activating oligomerization should benefit future discovery of biguanide skeleton-based novel SHMT2 inhibitors in cancer prevention and treatment.

Metformin is a pyridoxal-5′-phosphate (PLP)-competitive inhibitor of SHMT2 / Tramonti, A.; Cuyas, E.; Encinar, J. A.; Pietzke, M.; Paone, A.; Verdura, S.; Arbusa, A.; Martin-castillo, B.; Giardina, G.; Joven, J.; Vazquez, A.; Contestabile, R.; Cutruzzola', F; Menendez, J. A.. - In: CANCERS. - ISSN 2072-6694. - 13:16(2021). [10.3390/cancers13164009]

Metformin is a pyridoxal-5′-phosphate (PLP)-competitive inhibitor of SHMT2

Tramonti A.;Paone A.;Giardina G.;Contestabile R.;Cutruzzola' F
;
2021

Abstract

The anticancer actions of the biguanide metformin involve the functioning of the ser-ine/glycine one-carbon metabolic network. We report that metformin directly and specifically targets the enzymatic activity of mitochondrial serine hydroxymethyltransferase (SHMT2). In vitro competitive binding assays with human recombinant SHMT1 and SHMT2 isoforms revealed that metformin preferentially inhibits SHMT2 activity by a non-catalytic mechanism. Computational docking coupled with molecular dynamics simulation predicted that metformin could occupy the cofactor pyridoxal-5′-phosphate (PLP) cavity and destabilize the formation of catalytically active SHMT2 oligomers. Differential scanning fluorimetry-based biophysical screening confirmed that metformin diminishes the capacity of PLP to promote the conversion of SHMT2 from an inactive, open state to a highly ordered, catalytically competent closed state. CRISPR/Cas9-based disruption of SHMT2, but not of SHMT1, prevented metformin from inhibiting total SHMT activity in cancer cell lines. Isotope tracing studies in SHMT1 knock-out cells confirmed that metformin decreased the SHMT2-channeled serine-to-formate flux and restricted the formate utilization in thymidylate synthesis upon overexpression of the metformin-unresponsive yeast equivalent of mitochondrial complex I (mCI). While maintaining its capacity to inhibit mitochondrial oxidative phosphorylation, metformin lost its cytotoxic and antiproliferative activity in SHMT2-null cancer cells unable to pro-duce energy-rich NADH or FADH2 molecules from tricarboxylic acid cycle (TCA) metabolites. As currently available SHMT2 inhibitors have not yet reached the clinic, our current data establishing the structural and mechanistic bases of metformin as a small-molecule, PLP-competitive inhibitor of the SHMT2 activating oligomerization should benefit future discovery of biguanide skeleton-based novel SHMT2 inhibitors in cancer prevention and treatment.
2021
Folate; glycine; one-carbon metabolism; serine; serine hydroxymethyltransferase
01 Pubblicazione su rivista::01a Articolo in rivista
Metformin is a pyridoxal-5′-phosphate (PLP)-competitive inhibitor of SHMT2 / Tramonti, A.; Cuyas, E.; Encinar, J. A.; Pietzke, M.; Paone, A.; Verdura, S.; Arbusa, A.; Martin-castillo, B.; Giardina, G.; Joven, J.; Vazquez, A.; Contestabile, R.; Cutruzzola', F; Menendez, J. A.. - In: CANCERS. - ISSN 2072-6694. - 13:16(2021). [10.3390/cancers13164009]
File allegati a questo prodotto
File Dimensione Formato  
Tramonti_Metformin_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 6.14 MB
Formato Adobe PDF
6.14 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1573434
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact